Jocelyn Chapman, MD
Associate Professor
Ob/Gyn, Reproductive Sciences
School of Medicine

Single cell sequencing of early cancer and molecular testing of circulating blood will allow us to better understand the pathogenesis of early cancer and discover early molecular changes that may allow for an early detection test for ovarian cancer. Statistical methods, factor analysis, insights from evolutionary biology and an understanding of mutation processes at work in early cancer can help us distill out the important driver events and give us useful insights into the processes driving tumor evoluation.

I am specifically interested in using these integrated approaches to help understand the early events in the pathogenesis of ovarian, fallopian tube and peritoneal cancer (ovarian cancer) to improve our understanding of the development of this disease and to find novel ways of early detection. New discoveries regarding the carcinogenesis of BRCA-associated ovarian cancer have illuminated an opportunity to detect early-stage disease using molecular signals in circulation. As such, I have developed a prospective clinical trial to test whether detection of these molecular changes can predict early ovarian cancer and I am collaborating with clinicians and scientists across disciplines and across institutions with a goal to further our understanding of the early events in pelvic HGSC.

My clinical research interests involve optimizing the rational and economical delivery of medical care to our gynecologic oncology patients. To this end, we have piloted the successful implementation of clinical pathways to reduce hospital stays post-operatively. Such process improvement involves multi-disciplinary efforts and cross-discipline collaboration. Our current efforts are focused at improving the patient education experience related to peri-operative care in partnership with our Gynecologic Oncology nursing team. Previous process improvements have involved implementing post-operative immunonutrition with a demonstrable reduction in post-operative wound complications and implementation of post-surgical pathways with a demonstrable reduction in hospital length of stay.

• Evidence-based prescribing of opioids after laparotomy: A quality-improvement initiative in gynecologic oncology.
  Gynecologic oncology reports 2024 Kay AH, Levy R, Hills N, Jang A, Mcgough-Maduena A, Dematteo N, Mark M, Ueda S, Chen LM, Chapman JS
• Exploring the relationship between language, postoperative pain, and opioid use.
  AJOG global reports 2024 Levy RA, Kay AH, Hills N, Chen LM, Chapman JS
• Roadmap to safety: a single center study of evidence-informed approach to placenta accreta spectrum.
  Frontiers in surgery 2024 Levy RA, Diala PC, Rothschild HT, Correa J, Lehrman E, Markley JC, Poder L, Rabban J, Chen LM, Gras J, Sobhani NC, Cassidy AG, Chapman JS
• The past, present, and future of opioid prescribing: Perioperative opioid use in gynecologic oncology patients after laparotomy at a single institution from 2012 to 2021.
  Gynecologic oncology reports 2023 Kay AH, Othieno A, Boscardin J, Chen LL, Alvarez EA, Swanson M, Ueda S, Chen LM, Chapman JS
• Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer.
  Gynecologic oncology 2022 Hou JY, Chapman JS, Kalashnikova E, Pierson W, Smith-McCune K, Pineda G, Vattakalam RM, Ross A, Mills M, Suarez CJ, Davis T, Edwards R, Boisen M, Sawyer S, Wu HT, Dashner S, Aushev VN, George GV, …
• Discovering dominant tumor immune archetypes in a pan-cancer census.
  Cell 2021 Combes AJ, Samad B, Tsui J, Chew NW, Yan P, Reeder GC, Kushnoor D, Shen A, Davidson B, Barczak AJ, Adkisson M, Edwards A, Naser M, Barry KC, Courau T, Hammoudi T, Argüello RJ, Rao AA, Olshen AB, …
• Better late than never: Brachytherapy is more important than timing in treatment of locally advanced cervical cancer.
  Gynecologic oncology 2021 Korenaga TK, Yoshida EJ, Pierson W, Chang J, Ziogas A, Swanson ML, Chapman JS, Sinha S, Chen LM
• Survival impact of bowel resection at the time of interval cytoreductive surgery for advanced ovarian cancer.
  Gynecologic oncology reports 2021 McNamara B, Guerra R, Qin J, Craig AD, Chen LM, Varma MG, Chapman JS
• Primary treatment of advanced ovarian cancer: how does the 'real world' practice?
  Future oncology (London, England) 2021 Craig AD, Garcia E, Peters PN, Chen LM, Chapman JS
• PET-detected asymptomatic recurrence is associated with improved survival in recurrent cervical cancer.
  Abdominal radiology (New York) 2020 Peters PN, Pierson WE, Chen LM, Westphalen AC, Chapman JS, Hsu IC
• An integrated molecular profile of endometrioid ovarian cancer.
  Gynecologic oncology 2020 Pierson WE, Peters PN, Chang MT, Chen LM, Quigley DA, Ashworth A, Chapman JS
• Medicaid and Medicare payer status are associated with worse surgical outcomes in gynecologic oncology.
  Gynecologic oncology 2019 Ahmad TR, Chen LM, Chapman JS, Chen LL
• Inflammatory Myofibroblastic Tumor Associated With the Placenta: Short Tandem Repeat Genotyping Confirms Uterine Site of Origin.
  The American journal of surgical pathology 2018 Ladwig NR, Schoolmeester JK, Weil L, Chapman JS, Zaloudek C, Umetsu SE
• Disparities in genetics assessment for women with ovarian cancer: Can we do better?
  Gynecologic oncology 2018 Manrriquez E, Chapman JS, Mak J, Blanco AM, Chen LM
• PET/MR Imaging in Gynecologic Oncology.
  Magnetic resonance imaging clinics of North America 2017 Ohliger MA, Hope TA, Chapman JS, Chen LM, Behr SC, Poder L
• In Reply.
  Obstetrics and gynecology 2017 Chen LM, Chen LL, Chapman JS
• Genomic insights in gynecologic cancer.
  Current problems in cancer 2016 Roddy E, Chapman J
• Enhanced Recovery Pathways for Improving Outcomes After Minimally Invasive Gynecologic Oncology Surgery.
  Obstetrics and gynecology 2016 Chapman JS, Roddy E, Ueda S, Brooks R, Chen LL, Chen LM
• Re: "Clinical Sequencing Contributes to a BRCA-Associated Cancer Rediagnosis That Guides an Effective Therapeutic Course".
  Journal of the National Comprehensive Cancer Network : JNCCN 2016 Klauschen F, Bläker H, Stenzinger A, Chapman JS, Collisson EA, Taylor BS
• The Authors Respond.
  Journal of the National Comprehensive Cancer Network : JNCCN 2016 Chapman JS, Collisson EA, Taylor BS
• Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
  Nature biotechnology 2015 Chang MT, Asthana S, Gao SP, Lee BH, Chapman JS, Kandoth C, Gao J, Socci ND, Solit DB, Olshen AB, Schultz N, Taylor BS
• Post-operative enteral immunonutrition for gynecologic oncology patients undergoing laparotomy decreases wound complications.
  Gynecologic oncology 2015 Chapman JS, Roddy E, Westhoff G, Simons E, Brooks R, Ueda S, Chen L
• Routine bimanual pelvic examinations: practices and beliefs of US obstetrician-gynecologists.
  American journal of obstetrics and gynecology 2012 Henderson JT, Harper CC, Gutin S, Saraiya M, Chapman J, Sawaya GF
• H1N1 influenza in pregnancy: cause for concern.
  Obstetrics and gynecology 2009 Saleeby E, Chapman J, Morse J, Bryant A
• Neurodevelopmental outcomes of congenital diaphragmatic hernia survivors followed in a multidisciplinary clinic at ages 1 and 3.
  Journal of pediatric surgery 2008 Friedman S, Chen C, Chapman JS, Jeruss S, Terrin N, Tighiouart H, Parsons SK, Wilson JM
• Long-term functional impact of congenital diaphragmatic hernia repair on children.
  Journal of pediatric surgery 2007 Chen C, Jeruss S, Chapman JS, Terrin N, Tighiouart H, Glassman E, Wilson JM, Parsons SK